View Financial HealthTegoScience 배당 및 자사주 매입배당 기준 점검 0/6TegoScience 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 17TegoScience Inc., Annual General Meeting, Mar 27, 2026TegoScience Inc., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 26, gomdallae-ro 57ga-gil, gangseo-gu, seoul South Korea분석 기사 • Jan 28Is TegoScience (KOSDAQ:191420) Weighed On By Its Debt Load?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Risk • Nov 27New major risk - Revenue and earnings growthEarnings have declined by 9.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.2b revenue, or US$4.2m). Market cap is less than US$100m (₩128.1b market cap, or US$87.6m).분석 기사 • Sep 01Is TegoScience (KOSDAQ:191420) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Jul 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.2b (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risks Revenue is less than US$5m (₩6.8b revenue, or US$5.0m). Market cap is less than US$100m (₩135.2b market cap, or US$98.9m).공시 • May 29TegoScience Inc. announced that it has received KRW 27 billion in fundingOn May 27, 2025, TegoScience Inc. closed the transaction.New Risk • May 20New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risk Revenue is less than US$5m (₩6.8b revenue, or US$4.9m).Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩17,950, the stock trades at a trailing P/E ratio of 42.9x. Average trailing P/E is 28x in the Biotechs industry in South Korea. Total loss to shareholders of 5.3% over the past three years.분석 기사 • Mar 28We Think That There Are Some Issues For TegoScience (KOSDAQ:191420) Beyond Its Promising EarningsTegoScience Inc.'s ( KOSDAQ:191420 ) robust recent earnings didn't do much to move the stock. We believe that...공시 • Mar 07TegoScience Inc., Annual General Meeting, Mar 28, 2025TegoScience Inc., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: auditorium, 26, gomdallae-ro 57ga-gil, gangseo-gu, seoul South KoreaNew Risk • Jan 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (₩6.9b revenue, or US$4.7m). Market cap is less than US$100m (₩135.7b market cap, or US$93.0m).Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩14,720, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 30% over the past three years.New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩120.9b market cap, or US$84.1m).Valuation Update With 7 Day Price Move • Dec 02Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩12,360, the stock trades at a trailing P/E ratio of 27.1x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 39% over the past three years.New Risk • Nov 06New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₩7.0b (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (₩7.0b revenue, or US$5.0m). Market cap is less than US$100m (₩137.6b market cap, or US$98.1m).Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩17,300, the stock trades at a trailing P/E ratio of 41.3x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 29% over the past three years.Valuation Update With 7 Day Price Move • Aug 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩16,000, the stock trades at a trailing P/E ratio of 38.2x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 43% over the past three years.New Risk • Aug 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩122.1b (US$89.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₩122.1b market cap, or US$89.5m).New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.6b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩137.6b market cap, or US$99.7m).New Risk • Mar 22New major risk - Revenue and earnings growthEarnings have declined by 0.06% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.06% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).New Risk • Nov 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩81.3b market cap, or US$61.3m).Valuation Update With 7 Day Price Move • Nov 30Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₩13,450, the stock trades at a trailing P/E ratio of 79.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 40% over the past three years.Is New 90 Day High Low • Feb 23New 90-day low: ₩26,100The company is down 2.0% from its price of ₩26,700 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.분석 기사 • Feb 16Are TegoScience Inc.'s (KOSDAQ:191420) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?TegoScience (KOSDAQ:191420) has had a rough month with its share price down 6.9%. It seems that the market might have...분석 기사 • Jan 12How Much Of TegoScience Inc. (KOSDAQ:191420) Do Insiders Own?A look at the shareholders of TegoScience Inc. ( KOSDAQ:191420 ) can tell us which group is most powerful. Institutions...Is New 90 Day High Low • Dec 22New 90-day high: ₩30,650The company is up 6.0% from its price of ₩28,850 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 14% over the same period.분석 기사 • Dec 08Did You Miss TegoScience's (KOSDAQ:191420) Impressive 137% Share Price Gain?When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...Is New 90 Day High Low • Oct 15New 90-day low: ₩26,050The company is down 20% from its price of ₩32,600 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 A191420 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: A191420 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장TegoScience 배당 수익률 vs 시장A191420의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (A191420)n/a시장 하위 25% (KR)1.0%시장 상위 25% (KR)3.8%업계 평균 (Biotechs)0.5%분석가 예측 (A191420) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 A191420 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 A191420 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 A191420 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: A191420 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YKR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 09:42종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스TegoScience Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Seung-Ho LeeNH Investment & Securities Co., Ltd.
공시 • Mar 17TegoScience Inc., Annual General Meeting, Mar 27, 2026TegoScience Inc., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 26, gomdallae-ro 57ga-gil, gangseo-gu, seoul South Korea
분석 기사 • Jan 28Is TegoScience (KOSDAQ:191420) Weighed On By Its Debt Load?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Risk • Nov 27New major risk - Revenue and earnings growthEarnings have declined by 9.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.2b revenue, or US$4.2m). Market cap is less than US$100m (₩128.1b market cap, or US$87.6m).
분석 기사 • Sep 01Is TegoScience (KOSDAQ:191420) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Jul 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.2b (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risks Revenue is less than US$5m (₩6.8b revenue, or US$5.0m). Market cap is less than US$100m (₩135.2b market cap, or US$98.9m).
공시 • May 29TegoScience Inc. announced that it has received KRW 27 billion in fundingOn May 27, 2025, TegoScience Inc. closed the transaction.
New Risk • May 20New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risk Revenue is less than US$5m (₩6.8b revenue, or US$4.9m).
Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩17,950, the stock trades at a trailing P/E ratio of 42.9x. Average trailing P/E is 28x in the Biotechs industry in South Korea. Total loss to shareholders of 5.3% over the past three years.
분석 기사 • Mar 28We Think That There Are Some Issues For TegoScience (KOSDAQ:191420) Beyond Its Promising EarningsTegoScience Inc.'s ( KOSDAQ:191420 ) robust recent earnings didn't do much to move the stock. We believe that...
공시 • Mar 07TegoScience Inc., Annual General Meeting, Mar 28, 2025TegoScience Inc., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: auditorium, 26, gomdallae-ro 57ga-gil, gangseo-gu, seoul South Korea
New Risk • Jan 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (₩6.9b revenue, or US$4.7m). Market cap is less than US$100m (₩135.7b market cap, or US$93.0m).
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩14,720, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 30% over the past three years.
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩120.9b market cap, or US$84.1m).
Valuation Update With 7 Day Price Move • Dec 02Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩12,360, the stock trades at a trailing P/E ratio of 27.1x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 39% over the past three years.
New Risk • Nov 06New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₩7.0b (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (₩7.0b revenue, or US$5.0m). Market cap is less than US$100m (₩137.6b market cap, or US$98.1m).
Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩17,300, the stock trades at a trailing P/E ratio of 41.3x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 29% over the past three years.
Valuation Update With 7 Day Price Move • Aug 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩16,000, the stock trades at a trailing P/E ratio of 38.2x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 43% over the past three years.
New Risk • Aug 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩122.1b (US$89.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₩122.1b market cap, or US$89.5m).
New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.6b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩137.6b market cap, or US$99.7m).
New Risk • Mar 22New major risk - Revenue and earnings growthEarnings have declined by 0.06% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.06% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).
New Risk • Nov 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩81.3b market cap, or US$61.3m).
Valuation Update With 7 Day Price Move • Nov 30Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₩13,450, the stock trades at a trailing P/E ratio of 79.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 40% over the past three years.
Is New 90 Day High Low • Feb 23New 90-day low: ₩26,100The company is down 2.0% from its price of ₩26,700 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.
분석 기사 • Feb 16Are TegoScience Inc.'s (KOSDAQ:191420) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?TegoScience (KOSDAQ:191420) has had a rough month with its share price down 6.9%. It seems that the market might have...
분석 기사 • Jan 12How Much Of TegoScience Inc. (KOSDAQ:191420) Do Insiders Own?A look at the shareholders of TegoScience Inc. ( KOSDAQ:191420 ) can tell us which group is most powerful. Institutions...
Is New 90 Day High Low • Dec 22New 90-day high: ₩30,650The company is up 6.0% from its price of ₩28,850 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 14% over the same period.
분석 기사 • Dec 08Did You Miss TegoScience's (KOSDAQ:191420) Impressive 137% Share Price Gain?When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
Is New 90 Day High Low • Oct 15New 90-day low: ₩26,050The company is down 20% from its price of ₩32,600 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period.